Company
•
Hologic to Acquire Endomagnetics Ltd
Hologic, Inc. (Nasdaq: HOLX), a global leader in women’s health, has announced that it has signed a definitive agreement to acquire Endomagnetics Ltd (Endomag®), a privately held developer of breast cancer surgery technologies, for approximately $310 million, subject to working capital and other customary closing adjustments.
“We are delighted to attract the strength and focus of Hologic to power the next phase of our growth,” said Eric Mayes, CEO of Endomag. “Our team is encouraged by our cultural alignment and the potential to strengthen a broader portfolio of solutions to improve women’s health globally.”
Endomag generated approximately $35 million of revenue in calendar year 2023. The acquisition is expected to be slightly dilutive to Hologic’s non-GAAP earnings per share in fiscal 2024, break even in 2025 and accretive thereafter.
Completion of the acquisition is subject to customary closing conditions, including regulatory approvals.
→ For more information, please see the Hologic press release.